Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of targeted CD22/CD19 CAR-T cell immunotherapy for first-line consolidation therapy of high-risk invasive B-cell lymphoma.